Research Achievements

A task that seemed daunting 20 years ago – to change the world for patients diagnosed with juvenile myositis – is now within our reach. Children diagnosed with juvenile myositis today are doing better than at any other time in history.  

Thanks to your support, we have made crucial research investments that are resulting in better outcomes for patients, including:

  • Reducing diagnosis time by 75%, from 12 months to less than three months
  • Improving care and treatment protocols to help kids get the best care
  • Investing in research and partnerships to advance new treatments, such as rituximab, abatacept, and others.
     
    And this is just the beginning.  
     
    As we look to the future, we remain laser-focused on:
  • Accelerating scientific discovery to better understand juvenile myositis so we can better treat it and one day prevent it
  • Expediting the development of new and repurposed treatments so patients have the most effective treatments without the devastating side effects
  • Helping patients get the best possible care
  • Investing in novel new approaches to the disease, including therapies at the genetic level that we hope could one day lead to long-term remission
     

One critical immediate goal is to expedite the availability of new treatments. Today, juvenile myositis is generally treated with drugs that broadly shut down the immune system, largely chemotherapy,and corticosteroids. These treatments can be quite effective, but they also block the immune responses necessary to fight off viruses and germs. This means there are a lot of side effects to these treatments. That is why we are investing in alternative approaches: to control the parts of the immune system that are not working correctly, while leaving the rest of the immune system functioning. We hope this will allow children to conquer juvenile myositis while living their best lives.
 
We could not accomplish any of this without you – our friends and families.
 
To learn more about your impact, we invite you to review our Impact Report here.

Vamorolone FAQ

Vamorolone FAQs in JM

With the looming FDA approval of the drug vamorolone in Duchenne muscular dystrophy, there are questions surrounding the drug’s status for trials in juvenile myositis. We have consulted with JM experts on the potential implications of a pending approval for the drug in another disease and what this currently means for JM patients living in the U.S.

Emma's Story of Hope, Giving Tuesday 2024

Emma’s Story of Hope – A Tale of Life-Changing Care

At 12 years old, Emma’s world was turned upside down. An energetic cheerleader who loved spending time with her friends, she suddenly found herself constantly fatigued, her muscles weak and aching. What began as mild discomfort quickly escalated into something far more serious.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.